ADC Therapeutics (ADCT) director logs RSU grant and tax withholding on Form 4

Rhea-AI Filing Summary

ADC Therapeutics director Sandor Victor reported routine equity compensation and related tax withholding. On June 1, 2026, he received 45,000 Common Shares through a grant of restricted stock units under the 2019 Equity Incentive Plan at a stated price of $0.00 per share. These RSUs vest on the earlier of one year from grant or the 2027 Annual Meeting of Shareholders, subject to continued board service. On June 3, 2026, the company withheld 12,600 Common Shares at $3.08 per share to cover his tax obligations upon vesting of previously granted RSUs, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Victor directly owns 140,686 Common Shares of ADC Therapeutics.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sandor Victor

Role null

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares	12,600	$3.08	$39K
Grant/Award	Common Shares	45,000	$0.00	--

Holdings After Transaction: Common Shares — 140,686 shares (Direct, null)

Footnotes (1)

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Key Figures

RSU grant size: 45,000 Common Shares Tax withholding shares: 12,600 Common Shares Withholding price: $3.08 per share +2 more

5 metrics

RSU grant size 45,000 Common Shares Annual director RSU grant on June 1, 2026

Tax withholding shares 12,600 Common Shares Shares withheld for tax obligations on June 3, 2026

Withholding price $3.08 per share Value used for tax-withholding disposition

Shares owned after transactions 140,686 Common Shares Direct ownership following grant and tax withholding

Transaction codes A (grant) and F (tax withholding) Non-derivative Form 4 transactions reported

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, tax withholding obligations, grant, award, or other acquisition, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"made under the Issuer's 2019 Equity Incentive Plan for service as a Director"

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting"

grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

Payment of exercise price or tax liability by delivering securities financial

"transaction code description: Payment of exercise price or tax liability by delivering securities"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandor Victor

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		A		45,000(1)	A	$0	153,286	D
Common Shares	06/03/2026		F(2)		12,600	D	$3.08	140,686	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa, Kallebo, as Attorney-in-Fact for Victor Sandor	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ADC Therapeutics (ADCT) director Sandor Victor report?

Director Sandor Victor reported a routine equity grant and tax withholding. He received 45,000 ADC Therapeutics Common Shares via restricted stock units and had 12,600 shares withheld by the company to satisfy tax obligations tied to vesting of earlier RSU awards.

Was Sandor Victor’s ADC Therapeutics (ADCT) Form 4 a market sale of shares?

The Form 4 does not show a market sale. Instead, 12,600 ADC Therapeutics Common Shares were withheld by the issuer at $3.08 per share solely to cover Victor’s tax liabilities arising from vesting restricted share units previously granted under the company’s equity plan.

How many ADC Therapeutics (ADCT) shares did Sandor Victor receive in this Form 4 filing?

Victor received 45,000 ADC Therapeutics Common Shares through an annual restricted stock unit grant for board service. The grant was made under the company’s 2019 Equity Incentive Plan, with each RSU representing a contingent right to one Common Share upon vesting.

When do Sandor Victor’s new ADC Therapeutics (ADCT) RSUs vest?

The restricted stock units granted to Victor vest on the earlier of one year from the June 1, 2026 grant date or the 2027 Annual Meeting of Shareholders. Vesting remains contingent on his continued service as a director of ADC Therapeutics until that time.

How many ADC Therapeutics (ADCT) shares does Sandor Victor own after these transactions?

Following the reported RSU grant and tax withholding, Victor directly owns 140,686 ADC Therapeutics Common Shares. This figure reflects the net result after adding the 45,000-share award and subtracting the 12,600 shares withheld to satisfy his tax withholding obligations.